Latest News | Pact with Quantoom Biosciences to Boost Local Production of MRNA, SaRNA Vaccines: TechInvention CEO
Get latest articles and stories on Latest News at LatestLY. The recently entered partnership with Belgium-based Quantoom Biosciences will enhance local manufacturing of mRNA and self-amplifying RNA (saRNA) vaccines, a senior official of TechInvention, a leading biotech company, has said.
Mumbai, Mar 31 (PTI) The recently entered partnership with Belgium-based Quantoom Biosciences will enhance local manufacturing of mRNA and self-amplifying RNA (saRNA) vaccines, a senior official of TechInvention, a leading biotech company, has said.
During the visit of Belgian Princess Astrid on March 5, TechInvention entered into a collaboration with Belgium-based Quantoom Biosciences to establish an mRNA platform in its Global Collaborative Centre for Medical Countermeasures (GCMC) project.
Also Read | What Is NITI NCAER States Economic Forum Portal To Be Launched by Nirmala Sitharaman on April 1?.
The plant, which will come up in Navi Mumbai, is expected to start operations by October-November 2025, bringing advanced RNA technology to India and ensuring faster, cost-effective vaccine development, TechInvention Director and CEO Syed Ahmed said.
"This collaboration is a milestone in democratising RNA technology, ensuring affordable, scalable, and adaptable solutions for India and other low- and middle-income countries," Ahmed told PTI.
"We believe that by making RNA-based medicines accessible and scalable in India, we are contributing to a more equitable global healthcare ecosystem,” Quantoom Biosciences CEO José Castillo said.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)